Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone as Adjunctive Therapy in Major Depressive Disorder
NCT07781293Phase 3Not yet recruiting
- Sponsor
- Bukwang Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Oct 2027
01
Overview
A Phase 3 trial of lurasidone in major depressive disorder (MDD), sponsored by Bukwang Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
lurasidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07781293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07781293.